Loading…
Fierce Drug Dev Forum 2019 has ended
avatar for Abbas Kazimi

Abbas Kazimi

NIMBUS THERAPEUTICS
Vice President, Head of Business Development
Abbas Kazimi is Vice President of Business Development at Nimbus where he is responsible for corporate and strategic development, establishing partnerships, and leading collaborations. Abbas joined Nimbus in 2014 and has driven key transactions at Nimbus as well as helped lead the licensing agreement with Genentech in 2015, the sale of Nimbus’ clinical NASH program to Gilead up to an aggregate of $1.2 billion in 2016, and the strategic alliances with Celgene announced in 2017 and 2019. Prior to joining Nimbus, Abbas spent a decade in planning & executing strategic transactions for life sciences clients with industry partners and financial investors across the globe. He was most recently at Extera Partners, LLC, a corporate development services firm, where he focused on biopharma partnering, financing, M&A, and corporate strategy efforts for a breadth of private, life sciences companies. Prior to Extera, Abbas was a business development analyst at JSB-Partners, LLC, a corporate transaction firm started by the founding team of MPM Capital, LP, to specialize in investment banking and healthcare advisory services.

Abbas holds an MA from Harvard University and a BA from the University of Texas at Austin.